BIOMÉRIEUX: Q2 growth in-line with expectations, disappointing underlying profitability | NEUTRAL | EUR70
BIOMÉRIEUX - NEUTRAL | EUR70Q2 growth in-line with expectations, disappointing underlying profitability
Growth accelerated in Q2, meeting consensus expectations
30bp cEBIT margin decline, underlying margin declining 50bp
Reiterated guidance leaves no room to upside revision
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.